Proposal No. 1 7 - 1 0 3

Proposal for Task Force Consideration at the ISSC 2027 Biennial Meeting	1. a. X Growing Area b. ☐ Harvesting/Handling/Distribution c. ☐ Administrative

Submitter	US Food & Drug Administration (FDA)
Email	Melissa.Abbott@fda.hhs.gov
Proposal Subject	Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) Method for the Determination of Diarrhetic Shellfish Poisoning (DSP) Toxins in Shellfish.
Specific NSSP Guide Reference	Section IV. (Guidance Documents), Chapter II. (Growing Areas), Section .14 (Approved Laboratory Tests), Table 2 (Approved Methods for Biotoxin Testing) and Table 4 (Approved Limited Use Methods for Marine Biotoxin Testing)
Text of Proposal/ Requested Action	The intention is for this method to be an Approved Method for Marine Biotoxin Testing for clams and that it should appear in Section IV. (Guidance Documents), Chapter II. (Growing Areas), Section .14 (Approved Laboratory Tests), Table 2 (Approved Methods for Marine Biotoxin Testing) under the new heading: Biotoxin Type: Diarrhetic Shellfish Poisoning (DSP), and the applications should be (1) Growing Area Survey and Classification and (2) Controlled Relaying with the sample type of Shellfish for both. In addition, the method should also be included in Table 4 (Approved Limited Use Methods for Biotoxin Testing) for mussels and oysters. Additional validation will be submitted later in order to move mussels and oysters also to Table 2.
Public Health Significance	Method will be used to control hazard from Diarrhetic Shellfish Poisoning (DSP) in shellfish. No methods for DSP are currently listed in the NSSP yet shellfish harvesting closures have occurred due to these toxins in Texas since 2008, in the Pacific Northwest since 2011, and in the New England region since 2015. Regulatory laboratories in these regions are currently using best available science of LC-MS/MS according to the EU reference SOP for LC-MS/MS determination of lipophilic shellfish toxins
Cost Information	Capital equipment purchases: $500,000. Consumable cost per sample: $10.00

Research Needs Information

a. Proposed specific research need/ problem to be addressed	No methods are currently approved for use to control DSP hazard under the NSSP. The EU has adopted LC-MS/MS as the reference method for all of the lipophilic shellfish toxins, including DSP. This method is a modified version of the EU LC-MS/MS method optimized specifically for DSP.
b. Explain the relationship between proposed research need and program change recommended in the proposal	The proposal will provide full SLV data for the detection of DSP toxins in clams. Therefore it would be considered an Approved Method for clams (Table 2). Based on the immediate need for this method, it was felt that the submission should be made with the available data for clam with the intention of subsequent validation for mussels and oysters, for which only preliminary data is provided here. Therefore, the method should be considered for Approved Limited Use at this time for mussel and oyster and be included in Table 4 for these matrices.
c. Estimated cost	$10,000
d. Proposed sources of funding	FDA Internal Funding
e. Time frame anticipated	Submission of all materials I order to

	be reviewed prior to the 2017 bi-annual ISSC meeting
Action by 2017 Laboratory Committee	Recommended the following: 1) Adoption of Proposal 17-103 as an Approved Method for clams 2) Referral of Proposal 17-103 to an appropriate committee as determined by the Conference Chair to determine the appropriateness of the method for mussels and oysters
Action by 2017 Task Force I	Recommended adoption of Laboratory Committee recommendations on Proposal 17-103
Action by 2017 General Assembly	Adopted the recommendation of Task Force I on Proposal 17-103.
Action by FDA February 7, 2018	Concurred with Conference action on Proposal 17-103.
Action by 2019 Laboratory Committee	Recommended referral of Proposal 17-103 to an appropriate committee as determined by the Conference Chair
Action by 2019 Task Force I	Recommended adoption of Laboratory Committee recommendation on Proposal 17-103.
Action by 2019 General Assembly	Adopted recommendation of Task Force I on Proposal 17-103
Action by FDA February 21, 2020	Concurred with Conference action on Proposal 17-103
Action by the 2023 Laboratory Committee	Recommended referral of Proposal 17-103 to an appropriate committee as determined by the Conference Chairperson.
Action by 2023 Task Force I	Recommended adoption of the Laboratory Committee recommendation for Proposal 17-103
Action by 2023 General Assembly	Adopted the recommendation of Task Force I on Proposal 17-103
Action by FDA July 7, 2023	Concurred with Conference action on Proposal 17-103